ワクチンの開発と世界市場：2003年以降の市場予測

Vaccines were among the biggest medical breakthroughs of the 20th century. In the past

2 years, more than 15 new gene and immunotherapy medicines have come to market and at least 25 products are in late stage clinical trials.

Theta' s report covers trends and advancements in global vaccines markets that have occurred in 2001 and 2002. This study spotlights emerging therapeutic vaccine markets and focuses on novel therapeutics based on gene therapy, immunoproteins, and antibodies.

Key issues discussed in this report:

1.  Markets and advancements in:

• preventative pediatric vaccines
• adult at-risk vaccines
• therapeutic vaccines (including those based on antibodies, immunoproteins, DNA epitopes)

2. Delivery systems engineered to target diseased cells

3. Review of the progress in disease vaccine development for:

• cancer
• autoimmune disease
• cardiovascular disease
• gastrointestinal disorders
• sexually transmitted diseases
• infectious diseases

4. Profiles of the top vaccine companies, with mini-profiles of selected innovators

Table of Contents

1 Executive Summary

1.1 Overview

1.1.1 Pediatric Vaccines

1.1.2 Adult At-Risk Vaccines

1.1.3 Therapeutic Vaccines

1.2 Scope and Objectives of Report

1.3 Methodology of Investigation

1.4 Limitations of the Research

2 Trends and Issues in Vaccine Markets

2.1 Evolution of Pediatric Vaccines

2.1.1 Overview

2.1.2 National Immunization Data

2.1.3 Combination Vaccines: Boon or Bane?

2.1.4 Vaccine Shortages

2.2 Advance of Therapeutic Vaccines

2.2.1 Impact of Genomics and Proteomics

2.2.2 Patents and Intellectual Property

2.2.3 Biodefense Vaccines

2.2.4 HIV/AIDS Vaccine Research

2.3 Bumpy Road to Commercialization

2.3.1 Commercial Alliances and Agreements

2.3.2 Pricing and Marketing Issues

2.3.3 Market Demand Factors

2.4 Global Vaccine Initiatives and Support Organizations

2.4.1 World Organization Support Groups

2.4.2 Vaccine Initiatives by Country

3 Novel Vaccine Technologies

3.1 Introduction

3.2 Vaccine-Enabled Cancer Therapeutics

3.2.1 Description

3.2.2 Therapies in Development

3.3 Vaccine Drug Delivery Technologies

3.3.1 Vaccine Adjuvants

3.3.2 Vaccine Vectors

3.3.3 Oral, Nasal, Transdermal, and Edible Vaccines

3.4 Emerging Vaccine Targets

3.4.1 Therapeutic Vaccine Strategies

3.4.2 Preventative Vaccine Strategies

4 Market Analysis

4.1 Introduction

4.2 Market and Technology Trends Influencing Projections

4.3 Total World Market Size, Projections, and Shares

4.3.1 Market Analysis By Vaccine Type

4.3.2 Market Analysis by Geography

4.4 Pediatric Vaccines

4.4.1 Market Analysis

4.4.2 Unfavorable Economics of Pediatric Vaccines

4.4.3 Major Players

4.5 Adult At-Risk Vaccines

4.5.1 Market Analysis by Disease Indication

4.5.2 Major Players

4.6 Therapeutic Vaccines

4.6.1 Market Analysis by Technology

4.6.2 Cancer Vaccines

4.6.3 Major Players

5 Company Profiles: Major Players

5.1 Acambis plc (formerly Peptide Therapeutics/OraVax)

5.2 Active Biotech AB

5.3 AltaRex Corp.

5.4 Amgen Inc.

5.5 Antex Biologics Inc.

5.6 Antigenics, Inc.

5.7 Ariad Pharmaceuticals, Inc.

5.8 AstraZeneca Pharmaceuticals

5.9 AVANT Immunotherapeutics, Inc.

5.10 AVAX Technologies, Inc.

5.11 Aventis S.A./Aventis Pasteur

5.12 AVI BioPharma Inc.

5.13 Aviron

5.14 Bavarian Nordic A/S

5.15 Baxter Healthcare Corp.

5.16 Berna Biotech AG

5.17 Biogen, Inc.

5.18 BioSante Pharmaceuticals, Inc.

5.19 British Biotech plc

5.20 Cell Genesys, Inc.

5.21 Cell Pathways, Inc.

5.22 Celltech Group plc

5.23 CEL-SCI Corp.

5.24 Centocor Inc.

5.25 Chiron Corp.

5.26 Corixa Corp.

5.27 Dynavax Technologies Corp.

5.28 DynPort Vaccine Co. LLC (DVC)

5.29 Elan Corp., plc

5.30 EntreMed, Inc.

5.31 Epimmune Inc.

5.32 Genentech, Inc.

5.33 Genta Inc.

5.34 Genzyme Corp.

5.35 GlaxoSmithKline

5.36 Human Genome Sciences, Inc.

5.37 IDEC Pharmaceuticals Corp.

5.38 ILEX Oncology Inc.

5.39 ImClone Systems Inc.

5.40 Immunex Corp.

5.41 ImmunoGen, Inc.

5.42 Intercell AG

5.43 Intracel, LLC

5.44 Isis Pharmaceuticals, Inc.

5.45 Maxygen, Inc.

5.46 Medarex Inc.

5.47 MedImmune, Inc.

5.48 Merck & Co., Inc.

5.49 Millennium Pharmaceuticals, Inc.

5.50 Nabi Biopharmaceuticals

5.51 Novartis AG

5.52 Novavax, Inc.

5.53 Oxford BioMedica plc

5.54 PowderJect Pharmaceuticals plc

5.55 Progenics Pharmaceuticals, Inc.

5.56 Protein Design Labs Inc. (PDL)

5.57 Rhein Biotech N.V.

5.58 Roche (F. Hoffmann-La Roche Ltd.)

5.59 Schering-Plough Corp.

5.60 SciClone Pharmaceuticals, Inc.

5.61 Serono SA

5.62 Shire Pharmaceuticals Group plc/Shire Biologics

5.63 Transgene S.A.

5.64 Valentis, Inc.

5.65 VaxGen, Inc.

5.66 Vical Inc.

5.67 Wyeth

6 Company Profiles: Selected Innovators

6.1 Abbott Laboratories

6.2 Abgenix, Inc.

6.3 Advanced Biotherapy Concepts, Inc.

6.4 Aeterna Laboratories Inc.

6.5 Agensys, Inc. (formerly UroGenesys, Inc.)

6.6 Anosys, Inc. (formerly AP Cells)

6.7 Antigen Express, Inc.

6.8 Antisoma plc

6.9 Aphton Corp.

6.10 AtheroGenics, Inc.

6.11 Athersys, Inc.

6.12 AVANIR Pharmaceuticals (Xenerex Biosciences)

6.13 Avigen Inc.

6.14 Bharat Biotech International Ltd.

6.15 BioDelivery Sciences International, Inc.

6.16 Bio Farma (Persero)

6.17 Bio-Manguinhos

6.18 Biomira Inc.

6.19 Biosynexus Inc.

6.20 BioVex Ltd.

6.21 Cambridge Antibody Technology plc (CAT)

6.22 CancerVax Corp.

6.23 Celgene Corp.

6.24 Cell Matrix Inc.

6.25 Coley Pharmaceutical Group, Inc.

6.26 Crucell N.V.

6.27 Cytogen Corp.

6.28 CytRx Corp.

6.29 Dendreon Corp.

6.30 DOR Biopharma, Inc.

6.31 Eli Lilly and Co.

6.32 Eos Biotechnology

6.33 Epicyte Pharmaceutical Inc.

6.34 Galenica Pharmaceuticals Inc.

6.35 Genencor International, Inc.

6.36 Genitope Corp.

6.37 Genmab A/S

6.38 GenPhar, Inc.

6.39 GenVec, Inc.

6.40 Hollis-Eden Pharmaceuticals, Inc.

6.41 Hybridon, Inc.

6.42 ID Biomedical Corp.

6.43 igeneon AG

6.44 Immune Response Corp.

6.45 Immunitor

6.46 Immuno-Designed Molecules S.A.

6.47 Immunomedics, Inc.

6.48 INEX Pharmaceuticals Corp.

6.49 Inhibitex, Inc.

6.50 La Jolla Pharmaceutical Co.

6.51 Large Scale Biology Corp.

6.52 LifeTime Pharmaceuticals, Inc.

6.53 LigoCyte Pharmaceuticals, Inc.

6.54 Lorus Therapeutics Inc.

6.55 MediGene AG

6.56 MERIX Bioscience, Inc.

6.57 Micromet AG

6.58 Microscience Ltd.

6.59 Mojave Therapeutics, Inc.

6.60 Neurochem Inc.

6.61 Northwest Biotherapeutics, Inc.

6.62 NovaRx Corp.

6.63 Onyvax Ltd.

6.64 Onyx Pharmaceuticals, Inc.

6.65 Peregrine Pharmaceuticals, Inc. (formerly Techniclone Corp.)

6.66 Pharmexa A/S

6.67 Plexus Vaccine, Inc.

6.68 ProdiGene, Inc.

6.69 Protein Sciences Corp.

6.70 Sanofi-Synthelabo Inc.

6.71 Scancell, Ltd.

6.72 Seattle Genetics, Inc.

6.73 Serum Institute of India, Ltd. (SII)

6.74 Stressgen Biotechnologies Corp.

6.75 Therion Biologics Corp.

6.76 Vasogen Inc.

6.77 Viragen, Inc.

6.78 Xcyte Therapies, Inc.

6.79 Xenova plc

6.80 XTL Biopharmaceuticals Ltd.

6.81 ZymoGenetics, Inc.

7 Company Directory

Appendix A: Vaccine Products by Disease Indication

Appendix B: Vaccine Products by Technology

List of Tables

Table 2-1 Selected Biodefense and Infectious Disease Vaccine Developers

Table 2-2 Selected HIV Immunotherapy Products

Table 2-3 Selected Company Alliances in Immunotherapy Drug Development 2001-2002

Table 2-4 Selected Failures in Immunotherapy Development

Table 3-1 Selected Vaccine Vector Innovations

Table 3-2 Selected Innovations in Immunotherapy Drug Delivery

Table 4-1 World Vaccine Sales by Vaccine Type 2002

Table 4-2 World Vaccine Sales by Vaccine Type 2007

Table 4-3 World Vaccines Market Share by Vaccine Type 2002

Table 4-4 World Vaccines Market Share by Vaccine Type 2007

Table 4-5 World Vaccines Market Growth Rates by Vaccine Type 2002-2007

Table 4-6 World Vaccine Sales by Geographic Region 2002

Table 4-7 World Vaccine Sales by Geographic Region 2007

Table 4-8 World Vaccines Market Share by Geographic Region 2002

Table 4-9 World Vaccines Market Share by Geographic Region 2007

Table 4-10 World Vaccines Market Growth Rates by Geographic Region 2002-2007

Table 4-11 OECD Country-based Vaccine Manufacturers and Vaccines

Table 4-12 WHO Approved International Pediatric Vaccines as of March 2003

Table 4-13 World Pediatric and At-Risk Vaccine Sales by Company 2002

Table 4-14 World At-Risk Vaccine Sales by Disease Indication 2002

Table 4-15 World At-Risk Vaccine Sales by Disease Indication 2007

Table 4-16 World At-Risk Vaccines Market Share by Disease Indication 2002

Table 4-17 World At-Risk Vaccines Market Share by Disease Indication 2007

Table 4-18 World At-Risk Vaccines Market Growth Rates by Disease Indication 2002-2007

Table 4-19 World Therapeutic Vaccine and Immunotherapy Sales by Technology 2002

Table 4-20 World Therapeutic Vaccine and Immunotherapy Sales by Technology 2007

Table 4-21 World Therapeutic Vaccines and Immunotherapy Market Share by Technology 2002

Table 4-22 World Therapeutic Vaccines and Immunotherapy Market Share by Technology 2007

Table 4-23 World Therapeutic Vaccines and Immunotherapy Market Growth Rates by Technology 2002-2007

Table 4-24 Selected Therapeutic Vaccine Competitors, Company Revenues 2002

Table 4-25 Selected Therapeutic Vaccines and Immunotherapies, Product Revenues 2002

List of Figures

Figure 4-1 World Vaccine Sales by Vaccine Type 2002

Figure 4-2 World Vaccine Sales by Vaccine Type 2007

Figure 4-3 World Vaccines Market Share by Vaccine Type 2002

Figure 4-4 World Vaccines Market Share by Vaccine Type 2007

Figure 4-5 World Vaccines Market Growth Rates by Vaccine Type 2002-2007

Figure 4-6 World Vaccine Sales by Geographic Region 2002

Figure 4-7 World Vaccine Sales by Geographic Region 2007

Figure 4-8 World Vaccines Market Share by Geographic Region 2002

Figure 4-9 World Vaccines Market Share by Geographic Region 2007

Figure 4-10 World Vaccines Market Growth Rates by Geographic Region 2002-2007 .

Figure 4-11 World Pediatric and At-Risk Vaccine Sales by Company 2002

Figure 4-12 World At-Risk Vaccine Sales by Disease Indication 2002

Figure 4-13 World At-Risk Vaccine Sales by Disease Indication 2007

Figure 4-14 World At-Risk Vaccines Market Share by Disease Indication 2002

Figure 4-15 World At-Risk Vaccines Market Share by Disease Indication 2007

Figure 4-16 World At-Risk Vaccines Market Growth Rates by Disease Indication 2002-2007 .

Figure 4-17 World Therapeutic Vaccine and Immunotherapy Sales by Technology 2002

Figure 4-18 World Therapeutic Vaccine and Immunotherapy Sales by Technology 2007

Figure 4-19 World Therapeutic Vaccines and Immunotherapy Market Share by Technology 2002

Figure 4-20 World Therapeutic Vaccines and Immunotherapy Market Share by Technology 2007

Figure 4-21 World Therapeutic Vaccines and Immunotherapy Market Growth Rates by Technology 2002-2007